Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M72 + AS01B
- Development stage
- Unknown
- Lead developer
- Gates Medical Research Institute
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
M72 + AS01B is an investigational **recombinant subunit vaccine candidate for tuberculosis (TB)**, composed of the M72 antigen and the AS01B adjuvant system. The **M72 antigen** is a recombinant fusion protein derived from two immunogenic *Mycobacterium tuberculosis* proteins, Mtb32A and Mtb39A, chosen for their ability to stimulate strong T-cell immune responses. The **AS01B adjuvant** is a liposome-based system containing two immunostimulants: monophosphoryl lipid A (MPL), a TLR4 agonist, and saponin QS-21 from Quillaja saponaria, designed to enhance both humoral and cellular immune responses—particularly robust CD4+ T-cell (Th1) responses and antibody production[1][2]. The vaccine is delivered intramuscularly and is currently in late-stage (PHASE3) clinical development for the prevention of active tuberculosis in infected or at-risk adults.
- Other names
- M72/AS01BM72/AS01E
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on M72 + AS01B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M72 + AS01B.